DEFA14A: Enhabit Urges Stockholders to Vote FOR Its Nominees Amidst Boardroom Battle

Enhabit is urging stockholders to vote for its nominees at the upcoming annual meeting on July 25, highlighting recent operational improvements and warning against the alternative slate proposed by AREX.

Summary

• Enhabit is urging stockholders to vote for its nine nominated directors at the upcoming Annual Meeting on July 25, 2024.
• The company highlights three consecutive quarters of strong operational results and emphasizes that its nominees possess the necessary experience to drive value creation.
• Enhabit's board has taken decisive actions to stabilize the business and position it for profitable growth.
• The company expects Adjusted EBITDA to be in the range of $24.5 million to $25.0 million and has reduced debt by $15 million.
• Independent proxy advisory firms ISS and Glass Lewis have recognized Enhabit's progress.
• Enhabit criticizes AREX's director candidates, citing a lack of relevant experience and potential conflicts of interest.
• The company believes AREX's plan and proposed shadow management committee could destroy stockholder value.
• Stockholders of record as of June 5, 2024, are entitled to vote at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document expresses a positive outlook regarding Enhabit's recent performance and strategic direction, while also conveying concern about the potential disruption from AREX's proposed changes. The sentiment is cautiously optimistic.

Positives

• Enhabit has achieved three consecutive quarters of strong operational results.
• The company expects Adjusted EBITDA to be in the range of $24.5 million to $25.0 million.
• Enhabit has reduced debt by $15 million.
• Independent proxy advisory firms ISS and Glass Lewis have recognized Enhabit's progress.
• Enhabit's board is almost wholly refreshed since its separation from Encompass two years ago.

Negatives

• AREX is attempting to replace a majority of Enhabit's directors.
• Enhabit's CEO has serious concerns about serving under the Transformation Committee as proposed by AREX.
• AREX's nominees lack current public accounting and internal control experience.

Risks

• AREX's plan and proposed shadow management committee could derail the progress Enhabit's Board and management team have made.
• Introducing AREX's unproven and inexperienced nominees to the Board could be disruptive.
• The company faces risks related to regulatory developments, reimbursement rates, economic conditions, and the ability to attract and retain key personnel.

Future Outlook

The company aims to transition its stability into further profitable growth.

Management Comments

• Enhabit has Achieved Three Consecutive Quarters of Strong Operational Results Demonstrating the Company is Executing the Right Plan and Strategy with the Right Board to Drive Value Creation
• Enhabit's Board is fit-for-purpose with directors that bring relevant industry and public company oversight expertise.
• We believe shifting course now, by introducing any of AREX's unproven and inexperienced nominees to the Board, would be reckless and potentially disruptive to the solid progress made over the past three quarters.

Industry Context

The announcement highlights the competitive landscape in the home health and hospice industry, with a focus on board composition and strategic direction.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document focuses on internal improvements and the qualifications of the board members relative to the challenges faced by Enhabit.

Legal Proceedings

• The company is involved in a lawsuit styled Enhabit, Inc. et al. v. Nautic Partners IX, L.P., et al. and pending in the Chancery Court of Delaware, and in which the Company has asserted claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers.

Stakeholder Impact

• The outcome of the director election will impact shareholders, employees, and potentially patients and referral sources.
• The company emphasizes the importance of maintaining stability and continuing progress for the benefit of all stakeholders.

Next Steps

• Stockholders are urged to vote on the YELLOW proxy card before the July 25 Annual Meeting.

Key Dates

Keywords

Enhabit, proxy vote, directors, annual meeting, AREX, EBITDA, debt reduction, home health, hospice